E-DRUG: new AIDS and TB drugs prequalified by WHO
-------------------------------------------------
[Thanks to Marta Darder (MSF) for the pointer and to Andy Gray (DRUGINFO)for
the comments; WB]
The WHO pre-qualification project has issued its 12th edition (dated 15
December 2003) of the "MANUFACTURERS AND SUPPLIERS WHOSE HIV-RELATED
MEDICINES HAVE BEEN FOUND ACCEPTABLE, IN PRINCIPLE, FOR PROCUREMENT BY UN
AGENCIES" -
see http://mednet3.who.int/prequal/hiv/hiv-suppliers.doc
Recently prequalified generics for AIDS:
- Ciprofloxacin 500mg tab from Cipla from the new site GOA
- Lamivudine 50mg/5ml oral solution from Cipla from the new site GOA
- Lamivudine + Stavudine 30mg and 40mg from Ranbaxy (Dewas): first double
FDCs prequalifiied!!!!
- Nevirapine 200mg tab from Cipla from the new site GOA
- Stavudine 30mg from Hetero
- Stavudine 30mg from Ranbaxy
- Zidovudine 100mg caps from Cipla from the new site GOA
- Zidovudine 50mg/5ml oral solution from Cipla from the new site GOA
- Zidovudine 50mg/5ml oral solution from Combinopharm
The list of pre-qualified products continues to grow, but some key agents
are still missing - such as efavirenz (from either an innovator or generic
source).
Another new feature is that products from more than one manufacturing site
owned by the same firm are approved in some cases (e.g. GSK's Zidovudine
solution from the Wellcome Foundation, Dartford, Kent as well as
Mississauga, Ontario; Cipla's Ciprofloxacin 500mg tablet from both Kurkumbh
and Goa).
The WHO pre-qualification project site also has lists for TB and malaria
medicines (see http://mednet3.who.int/prequal/default.shtml)
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug